Valuation: NEOVACS

Market Cap 4.09K 4.69K 3.87K 3.5K 6.56K 450K 6.61K 46.2K 17.82K 228K 17.6K 17.21K 733K P/E 2023 *
-
P/E 2024 -
Enterprise Value -201K -230K -190K -172K -322K -22.11M -325K -2.27M -876K -11.23M -865K -846K -36.01M EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99%
Yield 2023 *
-
Yield 2024 -
1 day-4.62%
1 week-27.06%
Current month-38.00%
1 month-63.75%
3 months-87.60%
6 months-97.52%
Current year-99.71%
1 week 0.25
Extreme 0.248
0.37
1 month 0.25
Extreme 0.248
0.89
Current year 0.25
Extreme 0.248
267
1 year 0.25
Extreme 0.248
4,200
3 years 0.25
Extreme 0.248
32,000,000
5 years 0.25
Extreme 0.248
351,920,000
10 years 0.25
Extreme 0.248
351,920,000
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 30/09/2020
Chief Tech/Sci/R&D Officer 56 -
Director TitleAgeSince
Chairman 87 27/05/2003
Director/Board Member - 30/04/2020
Chairman - -
Date Insider Type Main position Quantity % Market Cap. Importance
27/02/21 Sell

Chief Executive Officer

2,505,144 1.3796%
23/02/21 Sell

Chief Executive Officer

6,391,053 3.5196%
23/02/21 Sell

Chief Executive Officer

1,108,947 0.6107%
Change 5-day change 1-year change 3-year change Capi.($)
-4.62%-27.06%-99.99%-100.00% 47.74K
+0.22%-3.17%-1.61%+8.24% 45.81B
-4.36%-5.50%+324.07%+516.88% 43.91B
-0.32%+3.71%+44.55%+26.98% 44.39B
+0.46%-0.97%+4.76%+73.76% 39.4B
-0.17%-3.22%+9.45%+38.69% 31.26B
+3.30%-8.29% - - 15.75B
-0.65%+4.32%+24.18%+120.17% 17.32B
+1.66%+4.92%+18.42%+34.93% 14.73B
+0.19%-2.62%+79.59%+31.52% 13.03B
Average +0.07%-3.33%+44.82%+83.46% 26.56B
Weighted average by Cap. +0.39%-1.10%+73.42%+125.65%

Financials

2023 2024
Net sales 533K 612K 505K 457K 855K 58.68M 863K 6.03M 2.32M 29.8M 2.3M 2.25M 95.57M 434K 498K 411K 372K 696K 47.74M 702K 4.9M 1.89M 24.24M 1.87M 1.83M 77.75M
Net income -8.74M -10.03M -8.28M -7.49M -14.02M -962M -14.14M -98.79M -38.1M -488M -37.64M -36.81M -1.57B -32.91M -37.74M -31.18M -28.2M -52.78M -3.62B -53.25M -372M -143M -1.84B -142M -139M -5.9B
Net Debt -237K -271K -224K -203K -379K -26.02M -383K -2.67M -1.03M -13.21M -1.02M -996K -42.37M -205K -235K -194K -176K -329K -22.56M -332K -2.32M -894K -11.46M -883K -863K -36.74M
Logo NEOVACS
NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).
Employees
16
Date Price Change Volume
16/09/26 €0.2480 -4.62% 24,259
15/09/26 €0.2600 -7.14% 43,488
14/09/26 €0.2800 -6.67% 31,624
11/09/26 €0.3000 -6.25% 55,556
10/09/26 €0.3200 -8.60% 40,202
  1. Stock Market
  2. Stocks
  3. ALNEV Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!